CANDOL
Dead / Cancelled — Cancelled — Section 8 (as of 28 Jun 2024)
What this means for you
This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87117671
- Registration number
- 5353118
- Mark type
- Stylized text
- Filed
- 27 Jul 2016
- Published for opposition
- 26 Sept 2017
- Registered
- 12 Dec 2017
Goods and services
- Class 005 — Pharmaceuticals: Medical preparations in the nature of pharmaceuticals for the treatment of pain, asthma, chronic obstructive pulmonary disease (copd), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, glaucoma, nausea and vomiting, stroke, cancer, drug dependence, drug addiction, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, mental illness, and hepatic, renal, intestinal, autoimmune, metabolic, neurological, dermatological and cardiovascular disorders; sanitary preparations for medical purposes; vaccines; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations for injection for the treatment of pain, asthma, chronic obstructive pulmonary disease (copd), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders; drug delivery agents in the form of liquid medications, tablets, powders, capsules, inhalers, nasal sprays, orally disintegrating tablets, mouthwashes, that facilitate the delivery of pharmaceutical preparations; medicated transdermal drug delivery patches for use in the treatment of pain, asthma, chronic obstructive pulmonary disease (copd), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders; none of the aforementioned containing natural borage oil, being nutritional supplements, medicinal ointments, capsules for medicines, medicinal oils, dermatological preparations or for use in dermatology or in dietetics
- Class 010 — Medical apparatus: Inhalers for medical purposes; filters for inhalers for medical purposes; inhalers for medical use; inhalers for therapeutic use; drug delivery systems; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems; microneedle arrays for delivering medications; hypodermic syringes for injections for medical purposes; non-medicated transdermal drug delivery patches; medical apparatus and instruments for the treatment of pain, asthma, chronic obstructive pulmonary disease (copd), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders; medical apparatus and instruments for use in surgery
Owner
- Senzer Limited, London, GB
- Senzer Limited, London, GB
- Senzer Limited, London, GB
Prosecution history
- 28 Jun 2024 — CANCELLED SEC. 8 (6-YR)
- 14 Sept 2023 — WITHDRAWAL OF ATTORNEY GRANTED
- 14 Sept 2023 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED
- 12 Dec 2022 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 12 Dec 2017 — REGISTERED-PRINCIPAL REGISTER
- 26 Sept 2017 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Sept 2017 — PUBLISHED FOR OPPOSITION
- 06 Sept 2017 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Aug 2017 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Aug 2017 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 21 Aug 2017 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Aug 2017 — ASSIGNED TO LIE
- 24 Jul 2017 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 27 Apr 2017 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 27 Apr 2017 — LETTER OF SUSPENSION E-MAILED